InventisBio has signed a collaboration agreement with Betta Pharma under which InventisBio will out-license D-0316’s right in China to Betta Pharma for development. Betta Pharma will have the exclusive commercialization rights of D-0316 product in China.

D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor mainly used for the treatment of EGFR-mutant non-small cell lung cancer. The drug is currently in Phase I development in China. Betta Pharma will pay 230 million RMB in upfront and R&D milestones. InventisBio is eligible to receive sales milestones and royalties on sales.

Dr. Yaolin Wang, chairman and chief executive officer of InventisBio, said, “We are excited to work with Betta Pharma, a leader in oncology drug in China. Working together, we will speed up the development and market approval of D-0316 to meet the growing needs of lung cancer patients.”

Dr. Lieming Ding, chairman and chief executive officer of Betta Pharma, said, “We are pleased to work with InventisBio, a leader in oncology drug innovation. The collaboration will broaden the coverage of Betta Pharma’s capabilities in lung cancer treatment.”